孟鲁司特钠治疗喘息性疾病疗效分析

摘要

目的：观察孟鲁司特钠治疗喘息性疾病的临床疗效。方法80例喘息性疾病患儿，随机分成对照组(给予去除病因、对症平喘等治疗)和治疗组(在对照组基础上加用孟鲁司特钠治疗)，各40例。观察两组喘息时间、肺部哮鸣音消失时间、住院时间及随访3个月复发情况。结果治疗组喘息时间(4.5±0.3)d、肺部哮鸣音消失时间(4.8±0.1)d、住院时间(6.8±0.2)d及随访3个月复发率(5.0%)均优于对照组(P<0.05)。结论孟鲁司特钠治疗喘息性疾病可促使喘息消失，缩短病程，减少复发，疗效确切，安全性好，值得临床推广。%ObjectiveTo observe clinical effect by montelukast sodium in the treatment of asthmatic disease.MethodsA total of 80 children with asthmatic disease were randomly divided into control group (received causative factors removal and symptomatic asthma relief treatment) and treatment group (received additional montelukast sodium to control group therapy), with 40 cases in each group. Observation was made on wheezing time, lung wheezing rale disappearance time, hospital stay time and recurrence condition after 3-month follow-up in both groups.ResultsThe treatment group had all better wheezing time as (4.5±0.3) d, lung wheezing rale disappearance time as (4.8±0.1) d, hospital stay time as (6.8±0.2) d and recurrence rate after 3-month follow-up as 5.0% than those in the control group (P<0.05).ConclusionMontelukast sodium in treating asthmatic disease can accelerate cough disappearance, shorten disease course, and reduce recurrence, along with precise curative effect and good safety. It is worth clinical promotion.